Valuation: Moderna, Inc.

Market Cap 31.65B 27.75B 25.59B 23.71B 44.95B 3,006B 45.69B 307B 119B 1,482B 119B 116B 5,137B P/E 2026 *
-9.21x
P/E 2027 * -16.8x
Enterprise Value 28.05B 24.59B 22.68B 21.01B 39.83B 2,663B 40.49B 272B 106B 1,313B 105B 103B 4,552B EV / Sales 2026 *
13.4x
EV / Sales 2027 * 11.5x
Free-Float
92.69%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Moderna, Inc.

Manager TitleAgeSince
Chief Executive Officer 54 2011-02-28
Director of Finance/CFO 49 2022-09-05
President 50 2024-10-31
Director TitleAgeSince
Chairman 63 2012-01-31
Director/Board Member 54 2011-02-28
Director/Board Member 69 2019-12-10
Change 5-day change 1-year change 3-year change Capi.($)
+1.01%-39.82% - - 32.46B
+4.07%+8.45%+25.67%-2.34% 66.11B
-0.24%-3.13%+49.38%+223.97% 55.3B
+1.21%+42.20%+42.20%+42.20% 42.44B
-0.21%+7.44%-48.93%-54.50% 41.28B
-1.32%-4.79%+58.07%-25.22% 30.78B
+2.10%+4.14%+75.49%+90.19% 23.1B
-3.65%+8.93%+1.16%+184.50% 20.06B
-0.04%+3.85%+67.76%+135.89% 17.19B
+0.21%+5.05%+79.86%+363.23% 15.23B
Average +0.36%+4.29%+38.96%+106.44% 34.61B
Weighted average by Cap. +0.80%+4.01%+32.53%+79.12%

Financials

2026 *2027 *
Net sales 2.09B 1.83B 1.69B 1.57B 2.97B 199B 3.02B 20.27B 7.88B 97.89B 7.85B 7.68B 339B 2.54B 2.23B 2.06B 1.91B 3.61B 242B 3.67B 24.67B 9.59B 119B 9.55B 9.34B 413B
Net income -3.41B -2.99B -2.76B -2.55B -4.84B -324B -4.92B -33.06B -12.85B -160B -12.8B -12.52B -554B -1.85B -1.62B -1.5B -1.39B -2.63B -176B -2.67B -17.94B -6.97B -86.62B -6.95B -6.79B -300B
Net Debt -3.61B -3.16B -2.92B -2.7B -5.12B -342B -5.21B -34.96B -13.58B -169B -13.54B -13.24B -585B -2.27B -1.99B -1.84B -1.7B -3.23B -216B -3.28B -22.05B -8.57B -106B -8.54B -8.35B -369B
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB